Apollomics racks up $100 mln Series B
Apollomics Inc, a biopharmaceutical company focused on oncology combination therapies, has raised $100 million in Series B financing. CMB International led the round with participation from other investors that included OrbiMed Asia.
8 January 2019•1 min read
